Interpace Diagnostics And Predictive Oncology To Develop AI Powered Thyroid Cancer Diagnostics

Pixabay License | Source:  xresch , no changes made.
Advertisement img

Interpace Diagnostics Group, Inc. has executed an agreement with the Helomics division of Predictive Oncology, a company focused on applying artificial intelligence to personalized medicine and drug discovery.

Founded in 1998, based in Parsippany, New Jersey, Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Interpace’s Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management.

Interpace’s Biopharma Business is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

Featured Partners

Headquartered in the Greater Minneapolis Area, Minnesota, Predictive Oncology, formerly known as Precision Therapeutics, operates through its three wholly owned subsidiaries, Helomics, TumorGenesis and Skyline Medical. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical subsidiary markets its patented and FDA cleared STREAMWAY System which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.

As part of this agreement, the Companies expect to develop a pipeline of products that work seamlessly together to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations by leveraging Interpace’s Thyroid products, ThyGeNEXT® and ThyraMIR®, coupled with Helomics’ patient-derived tumor profiling and AI platform known as “D-CHIP.” Under the plan for this phase of the agreement Helomics will build a model using Interpace’s existing clinical data which can be utilized to identify druggable targets for treatment of indolent and aggressive thyroid cancers.

“The better we understand thyroid cancer, the better equipped we are to both diagnose and predict treatment outcomes.” … “We believe that this collaboration with Helomics is a significant step to help us better diagnose thyroid cancer, resulting in existing product line extensions as well as potentially new products and partnerships based on the AI-driven models Helomics is building.” – Jack Stover, CEO of Interpace Diagnostics

“Our collaboration with Interpace is a prime example of the capabilities that Helomics brings to improve diagnostics and BioPharma products.” … “We look forward to continuing this collaboration with Interpace and to future successful outcomes together.” – Gerald Vardzel, president of Helomics